-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Fulcrum Therapeutics, Raises Price Target to $24

Benzinga·12/08/2025 14:27:48
Listen to the news
Cantor Fitzgerald analyst Kristen Kluska maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and raises the price target from $15 to $24.